376 related articles for article (PubMed ID: 35036076)
1. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
[TBL] [Abstract][Full Text] [Related]
2. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
4. Differential polarization and the expression of efferocytosis receptor MerTK on M1 and M2 macrophages isolated from coronary artery disease patients.
Mohd Idrus FN; Ahmad NS; Hoe CH; Azlan M; Norfuad FA; Yusof Z; Wan Isa WYH; Mohamed Ali AA; Yvonne-Tee GB
BMC Immunol; 2021 Mar; 22(1):21. PubMed ID: 33761885
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
Liu Z; Wen J; Hu F; Wang J; Hu C; Zhang W
Cancer Sci; 2022 Feb; 113(2):432-445. PubMed ID: 34927311
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT
Zhang Y; Wang Y; Zhou D; Zhang LS; Deng FX; Shu S; Wang LJ; Wu Y; Guo N; Zhou J; Yuan ZY
Am J Physiol Cell Physiol; 2019 Oct; 317(4):C776-C787. PubMed ID: 31390228
[TBL] [Abstract][Full Text] [Related]
10. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
11. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy.
Li W; Wu F; Zhao S; Shi P; Wang S; Cui D
Cytokine Growth Factor Rev; 2022 Oct; 67():49-57. PubMed ID: 35871139
[TBL] [Abstract][Full Text] [Related]
12. Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
Werfel TA; Elion DL; Rahman B; Hicks DJ; Sanchez V; Gonzales-Ericsson PI; Nixon MJ; James JL; Balko JM; Scherle PA; Koblish HK; Cook RS
Cancer Res; 2019 Jan; 79(1):171-182. PubMed ID: 30413412
[TBL] [Abstract][Full Text] [Related]
13. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
Chen R; Huang B; Lian M; Wei Y; Miao Q; Liang J; Ou Y; Liang X; Zhang H; Li Y; Xiao X; Wang Q; You Z; Chai J; Gershwin ME; Tang R; Ma X
J Hepatol; 2023 Dec; 79(6):1478-1490. PubMed ID: 37659731
[TBL] [Abstract][Full Text] [Related]
14. YAP/STAT3 inhibited CD8
Wang C; Shen N; Guo Q; Tan X; He S
Cancer Med; 2023 Aug; 12(15):16295-16309. PubMed ID: 37329188
[TBL] [Abstract][Full Text] [Related]
15. RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer.
Zhou X; Li D; Xia S; Ma X; Li R; Mu Y; Liu Z; Zhang L; Zhou Q; Zhuo W; Ding K; Lin A; Liu W; Liu X; Zhou T
J Control Release; 2024 Feb; 366():128-141. PubMed ID: 38104775
[TBL] [Abstract][Full Text] [Related]
16. Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury.
Soliman E; Leonard J; Basso EKG; Gershenson I; Ju J; Mills J; de Jager C; Kaloss AM; Elhassanny M; Pereira D; Chen M; Wang X; Theus MH
J Neuroinflammation; 2023 Nov; 20(1):256. PubMed ID: 37941008
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G
Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
Wang J; Hu F; Yu P; Wang J; Liu Z; Bao Q; Zhang W; Wen J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5127-5138. PubMed ID: 36348018
[TBL] [Abstract][Full Text] [Related]
19. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
[TBL] [Abstract][Full Text] [Related]
20. Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages.
Wanke F; Gutbier S; Rümmelin A; Steinberg M; Hughes LD; Koenen M; Komuczki J; Regan-Komito D; Wagage S; Hesselmann J; Thoma R; Brugger D; Christopeit T; Wang H; Point F; Hallet R; Ghosh S; Rothlin CV; Patsch C; Geering B
Cell Death Dis; 2021 May; 12(6):538. PubMed ID: 34035216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
